A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

NCT02206035 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Hematopoietic Stem Cell Transplantation

Interventions

DRUG: Tacrolimus
DRUG: Methotrexate
DRUG: Tocilizumab

Sponsor

William R. Drobyski, MD